RESUMEN
The Akita mouse, one of the most frequently used animal models for the study of diabetes mellitus and its complications, carries a heterozygous missense mutation (C96Y) in the insulin 2 (Ins2) gene that results in proinsulin misfolding in the endoplasmic reticulum (ER), ER stress, pancreatic beta cell death and ultimately diabetes. Maintenance of Akita mice entails genotyping for the identification of the heterozygous Akita mutation. Current genotyping methods for the Akita mouse strain are time consuming, expensive, or needing special device. Here, we develop a simple, fast, cost-effective, and reliable genotyping methodology for the Akita mice. Utilizing the tetra-primer amplification-refractory mutation system polymerase chain reaction (ARMS-PCR) with primers that are specific for normal alleles or Akita mutant alleles, we obtained amplified PCR products that allowed us to distinguish between the wild-type (+/+), heterozygous (Ins2 Akita /+), and homozygous (Ins2 Akita /Ins2 Akita ) mice within 3 hours. These results present the ARMS-PCR analysis as highly desirable and suitable for the identification of the Akita mutation, which is expected to significantly facilitate and promote the Akita mouse-related studies.
RESUMEN
Neonates are predisposed to developing thrombocytopenia and neonates are affected by megakaryocytic disorders such as thrombocytopenia with absent radius syndrome and transient myeloproliferative disorder. Small double stranded non-coding microRNAs (miRNAs) have been shown to crucially involve in the regulation of stem-cell differentiation in normal as well as malignant haematopoiesis. The regulatory mechanism in developmental megakaryocytopoiesis and role of miRNAs in biological differences between adult and neonatal megakaryopoiesis is unknown. Here in we compared miR-99a levels in megakaryocytes (MKs) derived from cord blood (CB) and peripheral blood using qRT-PCR. CTDSPL is predicted as potential target of miR-99a and was confirmed by western blot. CTDSPL is shown to involve in regulation of cell growth and differentiation and exhibits tumor suppressor activity. We believe that miR-99a regulates CTDSPL, which induces the G1/S transition by increasing Cyclin expression and play a significant role in proliferation of CB-MKs.
Asunto(s)
Megacariocitos/metabolismo , MicroARNs/biosíntesis , Trombocitopenia/metabolismo , Adulto , Supervivencia Celular , Femenino , Fase G1 , Humanos , Recién Nacido , Masculino , Fase S , Proteínas Supresoras de Tumor/biosíntesisRESUMEN
Cancer is characterized by uncontrolled cell growth, invasion, and metastasis and possess threat to humans worldwide. The scientific community is facing numerous challenges despite several efforts to cure cancer. Though a number of studies were done earlier, the molecular mechanism of cancer progression is not completely understood. Currently available treatments like surgery resection, adjuvant chemotherapy, and radiotherapy are not completely effective in curing all the cancers. Recent advances in the antisense technology provide a powerful tool to investigate various cancer pathways and target them. Small interfering RNAs (siRNAs) could be effective in downregulating the cancer-associated genes, but their in vivo delivery is the main obstacle. DNA enzymes (DNAzymes) have great potential in the treatment of cancer due to high selectivity and significant catalytic efficiency. In this review, we are focusing on antisense molecules such as siRNA and DNAzymes in cancer therapeutics development. This review also describes the challenges and approaches to overcome obstacles involved in using siRNA and DNAzymes in the treatment of cancers.